Multiple Sclerosis Infusion Therapy: Ocrevus, Tysabri, and What to Expect

Your neurologist mentioned moving from your daily injection or pill to an infusion. Maybe it’s Ocrevus. Maybe it’s Tysabri, Lemtrada, or the newer Briumvi. The conversation moved fast, you walked out with a referral, and now you’re sitting at home trying to figure out what just happened.

MS is a chronic disease that asks a lot from you. Choosing a disease-modifying therapy (DMT) is one of the most consequential decisions you’ll make in managing it. Infusion therapies are not a step “up” or “down” from injections and pills. They’re a different category, with their own rhythm, their own monitoring, and their own tradeoffs.

This guide walks through the four main infusion DMTs used in the U.S. — what they are, how they’re different from one another, what the infusion experience actually looks like, what side effects to watch for, and how to think about the choice with your neurologist. We’ll also cover the JC virus question (a real consideration for Tysabri patients) and how a specialty pharmacy supports you through years of treatment.

Starting Ocrevus, Tysabri, or another MS infusion? Our pharmacists coordinate every infusion, monitor your labs and JCV status, and handle the insurance side. Most MS patients are with us for years. ▶  Call (949) 555-0100  ·  Talk to a Pharmacist

First, What “Infusion DMT” Actually Means

MS is an autoimmune disease in which your immune system attacks the myelin sheath that insulates your nerves. Disease-modifying therapies (DMTs) don’t cure MS. They slow how often relapses happen, how severe they are, and how quickly disability accumulates over time. The earlier and more consistently you use a DMT, the better the long-term picture tends to be.

DMTs come in three formats:

• Injectable DMTs (Copaxone, beta interferons, Plegridy) — taken at home, usually every few days to weekly
• Oral DMTs (Tecfidera, Gilenya, Aubagio, Mavenclad, Mayzent) — daily or short-course pills
• Infusion DMTs (Ocrevus, Tysabri, Lemtrada, Briumvi) — IV infusions every few weeks to twice yearly

Infusion DMTs are typically the most aggressive in terms of efficacy. They’re often chosen when the disease is highly active, when injection or oral therapies haven’t worked well, or as first-line for patients who’d rather have fewer, more impactful treatment days than daily medication.

The Four Main Infusion DMTs

Brand	Generic	MS Type	Frequency	Mechanism
Ocrevus	ocrelizumab	RRMS, PPMS	Every 6 months	B-cell depletion (anti-CD20)
Tysabri	natalizumab	RRMS	Every 4 weeks	Alpha-4 integrin blockade
Lemtrada	alemtuzumab	RRMS (high activity)	5-day + 3-day course, 1 year apart	T- and B-cell depletion
Briumvi	ublituximab	RRMS, active SPMS	Every 6 months after loading	B-cell depletion (anti-CD20)

RRMS = relapsing-remitting MS. PPMS = primary progressive MS. SPMS = secondary progressive MS. Ocrevus is currently the only FDA-approved DMT for primary progressive MS, which is part of why it’s prescribed so widely.

Ocrevus (ocrelizumab) — The Most-Prescribed Infusion DMT

Ocrevus depletes B-cells — a class of immune cells that play a key role in the autoimmune attack on myelin. By keeping B-cell levels low, Ocrevus reduces relapses, slows progression, and reduces the formation of new MS lesions on MRI.

How it’s given

Your first dose is split into two infusions, two weeks apart. After that, you receive a single full-dose infusion every six months. The first two infusions take about 2.5 hours each. Many patients qualify for a shorter 2-hour infusion schedule once they’ve tolerated the first full dose well.

What to expect at the infusion

You’ll receive premedication (typically methylprednisolone, an antihistamine, and acetaminophen) about 30 to 60 minutes before the Ocrevus starts. The medication runs slowly, with your nurse monitoring vital signs throughout. Most patients tolerate it well after the first dose.

Common side effects

• Infusion reactions — most common during the first dose, often manifesting as itching, flushing, throat irritation, or mild blood pressure changes. Most are mild and respond to slowing the infusion.
• Increased infection risk — particularly upper respiratory and urinary tract infections. Stay current on vaccines (especially shingles, flu, and COVID) before starting and report any infection signs promptly.
• Decreased immunoglobulin levels — some patients see slowly declining IgG levels over years on therapy. Your neurologist will monitor this with annual labs.

⚠️  A note on vaccines and Ocrevus B-cell depletion blunts your response to vaccines. Get all needed vaccines (especially shingles, COVID boosters, flu) at least 4-6 weeks before your first Ocrevus dose if possible. After starting Ocrevus, live vaccines are off-limits. Inactivated and mRNA vaccines are still given but may produce weaker antibody responses. Talk to your neurologist about timing.

Tysabri (natalizumab) — Highly Effective, with One Important Catch

Tysabri blocks alpha-4 integrin, a protein that lets immune cells cross from the bloodstream into the brain and spinal cord. By blocking this entry point, Tysabri stops the autoimmune attack on the central nervous system. It’s one of the most effective DMTs for relapsing MS, often dramatically reducing relapse rates and MRI lesion activity.

How it’s given

A single 1-hour infusion every 4 weeks. Most centers add a 1-hour observation period after the infusion. You’ll be at the infusion center for roughly 2 to 2.5 hours total, every month, indefinitely.

The JC virus consideration

Tysabri carries a risk of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection caused by reactivation of the JC virus (JCV). The risk is meaningful but manageable with monitoring:

• Before starting Tysabri, you’ll be tested for JCV antibodies. About 50% of adults have been exposed to JCV at some point and carry antibodies.
• If you’re JCV-negative, your PML risk on Tysabri is very low. You’ll be retested every 6 months because seroconversion can happen.
• If you’re JCV-positive, the risk depends on antibody index level, time on Tysabri, and prior immunosuppressant use. The risk increases meaningfully after 24 months of treatment.
• If your antibody index rises or other risk factors stack, your neurologist may recommend switching to a different DMT before the risk becomes unacceptable.

This isn’t meant to scare you away from Tysabri. It’s an extremely effective drug that has helped thousands of patients. But the JCV monitoring is non-negotiable, and knowing your JCV status is a basic part of being on Tysabri. Your specialty pharmacy and infusion center will keep this on schedule.

💡  Tysabri vs Ocrevus, in one sentence Tysabri tends to be slightly more effective at reducing relapse rates short-term but requires monthly infusions and ongoing JCV monitoring. Ocrevus is twice-yearly with broader MS-type coverage (including PPMS) and no JCV concern, but the immune effect is longer-lasting and harder to reverse if needed.

Switching between MS DMTs? Our pharmacists coordinate transitions, monitor washout periods, and handle the prior authorization for the new therapy. We’ve done thousands of MS DMT transitions. ▶  Schedule a Consult  ·  (949) 555-0100

Lemtrada (alemtuzumab) — A Different Kind of Course

Lemtrada is structurally different from the other infusion DMTs. Instead of ongoing maintenance, it’s given as two short courses one year apart. The first course is 5 consecutive days of infusion. The second course, 12 months later, is 3 consecutive days. After that, many patients don’t need another dose.

Lemtrada deeply depletes both T- and B-cells, then allows them to regenerate. The effect can last for years. It’s typically reserved for patients with highly active relapsing MS who haven’t responded well to other therapies, because the side effect profile is more demanding:

• Risk of secondary autoimmune conditions (especially thyroid disease, ITP, and rare kidney issues) — these can develop years after the last infusion, which is why Lemtrada requires monthly blood and urine monitoring for at least 4 years after the last dose.
• Infusion reactions are common and often more pronounced than with other DMTs.
• Increased risk of serious infections during the months following each course.

Lemtrada works extremely well for the right patient. The screening, monitoring, and long-term follow-up are intense, and patients typically work very closely with their MS center, neurologist, and specialty pharmacy throughout. We’ve supported many Lemtrada patients through this process — it requires more coordination than any other MS DMT.

Briumvi (ublituximab) — The Newer Anti-CD20

Briumvi is the most recently FDA-approved infusion DMT for relapsing MS. Like Ocrevus, it’s an anti-CD20 B-cell depleting therapy, but it’s engineered for shorter infusion times. After a loading dose split across the first two visits, maintenance infusions take about 1 hour, every 6 months.

For patients who would do well on Ocrevus but want the shorter chair time, Briumvi is increasingly an option. Long-term real-world data is still building, but the trial data showed strong relapse reduction and lesion control with a side effect profile similar to other anti-CD20 therapies.

How Do You and Your Neurologist Choose?

The right DMT depends on factors only your neurologist can fully weigh, but the conversation usually centers on:

1. MS type. PPMS narrows you to Ocrevus. Highly active RRMS opens up the more aggressive options like Tysabri or Lemtrada. Stable RRMS gives you more flexibility.
2. Disease activity. Frequent relapses or rapidly accumulating MRI lesions push toward more potent therapies.
3. JCV antibody status. Negative status makes Tysabri attractive. Positive status, especially with a high index, often steers toward Ocrevus or Briumvi.
4. Family planning. Pregnancy intentions affect timing and choice. B-cell depletors clear from your system more slowly than Tysabri. Discuss timing with your neurologist well before trying to conceive.
5. Lifestyle and logistics. Twice-yearly infusions vs monthly infusions vs short courses every year are very different commitments. Some patients prefer the consistency of monthly visits; others want fewer disruptions.
6. Insurance and access. Formulary status, prior authorization requirements, and out-of-pocket costs vary substantially across DMTs. A specialty pharmacy benefits investigation gives you the real numbers before the decision.

What an MS Infusion Day Actually Looks Like

Whether you’re starting Ocrevus, Tysabri, Lemtrada, or Briumvi, the rhythm of the infusion day is similar:

7. Lab and screening review. Before each infusion, your team verifies recent labs (CBC, liver function, IgG levels for Ocrevus and Briumvi, JCV status for Tysabri, urinalysis for Lemtrada).
8. Premedication. Most MS infusions include premeds (steroid, antihistamine, acetaminophen) given 30 to 60 minutes before the DMT to reduce infusion reaction risk.
9. The infusion itself. Anywhere from 1 hour (Briumvi maintenance) to 2.5+ hours (Ocrevus standard, Lemtrada days). You’ll have an IV started, vital signs checked frequently, and a nurse monitoring you throughout.
10. Observation. After the medication finishes, you’ll typically be observed for 30 to 60 minutes (longer for first doses) before you can leave.
11. Aftercare. Some patients feel completely normal afterward. Others feel mildly fatigued, headachy, or low-energy for 24 to 48 hours. Plan a quiet day if you can.

If you’ve never had an infusion before, our companion guide “What to Expect at Your First Infusion Therapy Appointment” walks through the experience step-by-step. The MS-specific layer is the premedication routine and the lab review. Otherwise, infusion day is the same calm, clinical experience for any infusion DMT.

How a Specialty Pharmacy Supports MS Patients

MS infusion therapy is a long-term partnership between you, your neurologist, your infusion center, and your specialty pharmacy. The specialty pharmacy’s role goes well beyond shipping medication:

• Coordinate every infusion delivery so the medication is at your infusion center on the right day, at the right temperature
• Track JCV status (for Tysabri patients), lab schedules, and IgG monitoring
• Manage prior authorization renewals, often required every 6 to 12 months
• Identify co-pay assistance programs, manufacturer support, and foundation grants
• Coordinate with your neurology team on dose timing, missed doses, and infusion adjustments
• Maintain 24/7 pharmacist availability for side effect questions, infection concerns, or vaccine timing

Most of our MS patients have been with us for three to seven years or more. Continuity matters when your therapy is measured in years. We know your timing, your insurance quirks, and your preferences, and we keep all of it running smoothly in the background so you can focus on the things that matter more than your medication.

Ready to talk through your MS infusion therapy? Whether you’re starting your first DMT, switching, or just want a second voice on the plan, our pharmacists are here. ▶  Contact River’s Edge  ·  (949) 555-0100

Frequently Asked Questions

Q: How quickly does MS infusion therapy start working?

It depends on the DMT. Tysabri begins suppressing immune cell migration within days. Ocrevus and Briumvi deplete B-cells within weeks. The clinical effect (fewer relapses, reduced MRI activity) becomes measurable over months. Most patients see their first MRI on therapy around 6 to 12 months in.

Q: Will I still need MRIs while on infusion therapy?

Yes. MRIs at baseline and at regular intervals (typically annually, sometimes more often early in therapy) are how your neurologist measures whether the DMT is working. New lesions on MRI can prompt a switch even if you feel symptom-free.

Q: Can I do MS infusions at home?

Some MS infusions can be administered at home with a trained infusion nurse, depending on the medication, your insurance, and your state. Tysabri home infusion has become more common. Ocrevus and Briumvi home infusion is offered in some markets. Lemtrada is given only in monitored settings due to the higher reaction risk. Ask your specialty pharmacy whether home infusion is available for your specific DMT.

Q: What happens if I miss or have to delay an infusion?

Don’t panic, but don’t ignore it either. Tysabri patients shouldn’t go more than 8 weeks between doses if avoidable, due to risk of disease rebound. Ocrevus and Briumvi have more flexibility (a few weeks late is usually fine). Call your specialty pharmacy and neurologist as soon as you know there will be a delay so the timing can be adjusted safely.

Q: How long will I be on infusion therapy?

For most MS patients, indefinitely. DMTs work as long as you take them and become less effective in their absence. Lemtrada is the exception — its course-based dosing means many patients don’t need additional therapy for years after their second course. Your neurologist may also discuss de-escalation in older patients with stable disease.

Q: Is MS infusion therapy safe during pregnancy?

Most MS DMTs are paused before conception and during pregnancy, with timing depending on which DMT. Tysabri can be continued in some cases up to early pregnancy under careful monitoring. B-cell depletors (Ocrevus, Briumvi) typically require a washout before conception. Lemtrada has its own timing considerations. This is a critical conversation to have with your neurologist before starting any DMT if pregnancy is on your horizon.

Q: How much does MS infusion therapy cost?

List prices for most MS infusion DMTs run $80,000 to $100,000+ per year, but few patients pay anywhere near that. With insurance, manufacturer co-pay assistance, and foundation grants, most patients pay between $0 and a few thousand dollars per year out-of-pocket. Your specialty pharmacy will run a benefits investigation and identify all assistance programs before treatment starts.

💡  Schema markup note for developers FAQPage schema for the 7 Q&As. Drug schema entries for Ocrevus, Tysabri, Lemtrada, Briumvi (with active ingredients ocrelizumab, natalizumab, alemtuzumab, ublituximab). MedicalCondition for multiple sclerosis with subTypes for relapsingRemittingMS, primaryProgressiveMS, secondaryProgressiveMS. Author Person schema with credential PharmD.

The Takeaway

MS infusion therapy is a long-term commitment, not a quick fix. The four main options — Ocrevus, Tysabri, Lemtrada, and Briumvi — each offer real disease control with their own rhythm and tradeoffs. The right choice for you depends on your MS type, your disease activity, your JCV status, your life plans, and your neurologist’s clinical judgment.

What you don’t have to figure out alone is the logistics. A specialty pharmacy that knows MS keeps the prior authorizations, the lab schedules, the co-pay assistance, and the infusion coordination running smoothly for years. The goal is for the medical part of having MS to take up as little of your life as possible — so the rest of your life has more room.